Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.
about
Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemmaClozapine-induced blood dyscrasias in Saudi Arab patients.Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.The risk of suicide after clozapine discontinuation: Cause for concern.Use of lithium in clozapine-induced neutropenia: a case report.The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study.Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study.Developments in the pharmacological treatment of schizophrenia.Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.Clozapine-Induced Late Agranulocytosis and Severe Neutropenia Complicated with Streptococcus pneumonia, Venous Thromboembolism, and Allergic Vasculitis in Treatment-Resistant Female Psychosis.Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials.Suicide risk in schizophrenia: learning from the past to change the future.Clozapine prescribing in the UK: views and experience of consultant psychiatrists.Toward a new prevention of suicide in schizophrenia.Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context.Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in IcelandAntipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year ComparisonRisk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.Suicide: An Indian perspectiveEstablishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.Successful rechallenge with clozapine following 'red alert'.Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study.Clozapine underutilization and discontinuation in African Americans due to leucopenia.Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children.Pharmacogenetic considerations in the treatment of psychiatric disorders.Where to position clozapine: re-examining the evidence.A systematic review of the evidence of clozapine's anti-aggressive effects.Pharmacological treatment of schizophrenia.Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature.Risk factors for suicide in schizophrenia: systematic review and clinical recommendations.Revisiting loxapine: a systematic review.Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations.Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada?Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia.Schizophrenia interventions in Vietnam: primary results from a cost-effectiveness study.Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients.Clozapine in Reducing Aggression and Violence in Forensic Populations.
P2860
Q26772273-B13981B6-0748-45B5-88AF-39150C585894Q26829834-491DE959-248C-4507-9ABC-078C78292D16Q33415861-5D7069B7-5419-4890-9700-7EE64F73F28BQ33713759-8F4AFADC-6681-42E5-95EC-26CE51281751Q33796327-B0F2F541-9925-4143-A9BC-592E4EF74B8BQ34204925-51B9D8BF-F92C-40D7-92DA-6E9CDF3F33E9Q34544343-3733B32B-324C-4338-B3BC-9ED2C89BCE83Q34644698-923903A8-3768-48D9-8C47-2D56E16E97DCQ34974846-238CF4F5-C170-49A1-BDCF-1881BCE27986Q35061441-2747BEEB-663D-4BFB-99A6-5C0DD6A3FBEAQ35113758-4048A771-2E78-46BF-977B-85155818266BQ35136085-F4C58A3B-3AC7-4652-8879-8D4FF5C4FABFQ35738863-DE21DF5E-D6F0-455C-87D3-2AB0B30122E1Q35906545-4920D89C-6C34-48FA-AF3A-38D29C519269Q35949240-A714C32E-3C9A-4331-83B6-ADC5547A4F6CQ36184331-87F6820D-6842-4744-951E-B499D2C7734DQ36220897-99C280B4-A44C-4BE4-B063-0BC94FDDB00CQ36325431-07766662-4D61-4D73-B391-BC4C3A98FFE2Q36440866-5330A8E1-63CB-4AA0-A9A8-D7AC93B391CDQ36562174-125CA5CA-B3F5-419F-A84C-7B10E8599DEDQ36605131-2BB6E847-5057-48B2-B3AF-A9076146F518Q36704371-F3718A94-1A70-416E-B855-EEAD81DDA689Q36715883-C1CAC029-8A4C-4122-A46F-F83D05174C6AQ36754155-0A38E54B-042E-4773-BB56-1E7863631F13Q37076129-17A49133-473C-4EB5-BA72-D9B6940BED93Q37409661-D04639E8-957D-4325-89D5-1C7581D19180Q37681573-E30BA42D-86ED-43AB-BBC6-6FD91EDB3634Q37801988-3B303238-195E-4877-BFE9-2F13BAEDB7CAQ37984684-5D8BE8C3-C02D-4096-B646-CDFD5BF03F23Q38051438-293C2142-C125-4D1C-8BD4-07D094E64795Q38113770-2DDB8D8E-F762-4FFF-A2C8-B32A87EC9884Q38250483-10D1EE9A-F60F-43C5-88AF-428A83B30448Q38413932-FFCC4F75-D828-4B3F-B974-1E05909B6601Q38659786-EB75B88E-E779-4EB0-B27F-D92A77AEBDA2Q38840211-D8263E56-19D1-42A7-B400-C75520BB35A4Q38867008-5DE89BDF-EA2E-4AD6-A676-2DB7B45B7397Q38979539-7EBEBD7C-9A14-4C81-9319-32FF240EAF88Q39080698-FD289E55-3E06-4884-B09C-672390433EF4Q39302471-40D9D9E8-7F0F-47B4-9409-0CD5057AC34FQ39393088-714E4A9B-535C-4F8C-BA1C-D0E7CDC1EE67
P2860
Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Active monitoring of 12,760 cl ...... and. Beyond pharmacovigilance.
@en
Active monitoring of 12,760 cl ...... and. Beyond pharmacovigilance.
@nl
type
label
Active monitoring of 12,760 cl ...... and. Beyond pharmacovigilance.
@en
Active monitoring of 12,760 cl ...... and. Beyond pharmacovigilance.
@nl
prefLabel
Active monitoring of 12,760 cl ...... and. Beyond pharmacovigilance.
@en
Active monitoring of 12,760 cl ...... and. Beyond pharmacovigilance.
@nl
P2093
P356
P1476
Active monitoring of 12,760 cl ...... and. Beyond pharmacovigilance.
@en
P2093
P304
P356
10.1192/BJP.175.6.576
P407
P577
1999-12-01T00:00:00Z